{"drugs":["Advate","Antihemophilic Factor (Recombinant) Plasma\/Albumin-Free","Xyntha"],"mono":{"0":{"id":"927833-s-0","title":"Generic Names","mono":"Antihemophilic Factor (Recombinant) Plasma\/Albumin-Free"},"1":{"id":"927833-s-1","title":"Dosing and Indications","sub":[{"id":"927833-s-1-4","title":"Adult Dosing","mono":"<ul><li>Each vial is labeled with the recombinant antihemophilic factor (rAHF) activity expressed in international units per vial. The expected peak increase in factor VIII level expressed as international units\/dL of plasma or percent of normal can be estimated by multiplying the dose administered per kg body weight (International units\/kg) by 2<\/li><li>If the patient's plasma factor VIII level fails to increase as expected or bleeding is not controlled after the expected dose, the presence of an inhibitor (neutralizing antibodies) should be suspected. If the inhibitor titer is less than 10 Bethesda units\/mL, administration of additional antihemophilic factor concentrate may neutralize the inhibitor and permit an appropriate hemostatic response.<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Minor bleeding, 10 to 20 international units\/kg IV to increase the circulating antihemophilic factor to 20% to 40% of normal every 12 to 24 hours for 1 to 3 days until bleeding episode is resolved or healing is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Moderate bleeding, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal every 12 to 24 hours for 3 days or more or until bleeding episode is resolved or healing is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Major bleeding, 30 to 50 international units\/kg IV to increase the circulating antihemophilic factor to 60% to 100% of normal every 8 to 24 hours until resolution of bleeding episode has occurred<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Minor bleeding, 10 to 20 international units\/kg IV to increase the circulating antihemophilic factor to 20% to 40% of normal every 12 to 24 hours as necessary until resolved, for at least 1 day<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Moderate bleeding, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal every 12 to 24 hours for 3 to 4 days or until adequate local hemostasis is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Major bleeding; 30 to 50 international units\/kg IV to increase the circulating antihemophilic factor to 60% to 100% of normal every 8 to 24 hours until bleeding is resolved<\/li><li><b>Bleeding, Routine; Prophylaxis - Hemophilia A:<\/b> Advate(R): 20 to 40 international units\/kg IV every other day (3 to 4 times weekly); alternatively, an every third day dosing regimen targeted to maintain factor VIII trough levels to 1% or greater may be used; adjust dose based on clinical response<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Advate(R): Minor surgery, single 30 to 50 international units\/kg IV bolus dose starting within 1 hour of surgery to increase the circulating antihemophilic factor to 60% to 100% of normal; may provide additional doses every 12 to 24 hours as needed to control bleeding; for dental procedures, consider adjunctive therapy<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Advate(R): Major surgery, 40 to 60 international units\/kg IV bolus dose preoperatively; verify 100% activity prior to surgery; maintenance bolus infusion, 40 to 60 international units\/kg to increase the circulating antihemophilic factor to 80% to 120% of normal, repeat infusions every 8 to 24 hours depending on desired level of factor VIII and state of wound healing<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Xyntha(R): Minor surgery, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal, repeat every 12 to 24 hours for 3 to 4 days or until local hemostasis is achieved; for tooth extraction, single IV infusion plus adjunctive oral antifibrinolytic therapy within 1 hour of surgery may be adequate<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Xyntha(R): Major surgery, 30 to 50 international units\/kg IV to increase the circulating antihemophilic factor to 60% to 100% of normal, repeat infusions every 8 to 24 hours until wound healing and local hemostasis are achieved<\/li><\/ul>"},{"id":"927833-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Each vial is labeled with the recombinant antihemophilic factor (rAHF) activity expressed in international units per vial. The expected peak increase in factor VIII level expressed as international units\/dL of plasma or percent of normal can be estimated by multiplying the dose administered per kg body weight (International units\/kg) by 2<\/li><li>If the patient's plasma factor VIII level fails to increase as expected or bleeding is not controlled after the expected dose, the presence of an inhibitor (neutralizing antibodies) should be suspected. If the inhibitor titer is less than 10 Bethesda units\/mL, administration of additional antihemophilic factor concentrate may neutralize the inhibitor and permit an appropriate hemostatic response.<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Minor bleeding, 10 to 20 international units\/kg IV to increase the circulating antihemophilic factor to 20% to 40% of normal every 12 to 24 hours (8 to 24 hours for patients younger than 6 years) for 1 to 3 days until bleeding episode is resolved or healing is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Moderate bleeding, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal every 12 to 24 hours (8 to 24 hours for patients younger than 6 years) for 3 days or more or until bleeding episode is resolved or healing is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Advate(R): Major bleeding, 30 to 50 international units\/kg IV to increase the circulating antihemophilic factor to 60% to 100% of normal every 8 to 24 hours (6 to 12 hours for patients younger than 6 years) until resolution of bleeding episode has occurred<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Minor bleeding, 10 to 20 international units\/kg IV to increase the circulating antihemophilic factor to 20% to 40% of normal every 12 to 24 hours as necessary until resolved, for at least 1 day<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Moderate bleeding, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal every 12 to 24 hours for 3 to 4 days or until adequate local hemostasis is achieved<\/li><li><b>Bleeding, Control and prevention - Hemophilia A:<\/b> Xyntha(R): Major bleeding, 30 to 50 international units IV\/kg to increase the circulating antihemophilic factor to 60% to 100% of normal every 8 to 24 hours until bleeding is resolved<\/li><li><b>Bleeding, Routine; Prophylaxis - Hemophilia A:<\/b> Advate(R): 20 to 40 international units\/kg IV every other day (3 to 4 times weekly); alternatively, an every third day dosing regimen targeted to maintain factor VIII trough levels to 1% or greater may be used; adjust dose based on clinical response<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Advate(R): Minor surgery, single 30 to 50 international units\/kg IV bolus dose starting within 1 hour of surgery to increase the circulating antihemophilic factor to 60% to 100% of normal; for dental procedures, consider adjunctive therapy<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Advate(R): Major surgery, 40 to 60 international units\/kg IV bolus dose preoperatively; verify 100% activity prior to surgery, maintenance bolus infusion, 40 to 60 international units\/kg to increase the circulating antihemophilic factor to 80% to 120% of normal, repeat infusions every 8 to 24 hours (6 to 24 hours for patients younger than 6 years) depending on desired level of factor VIII and state of wound healing<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Xyntha(R): Minor surgery, 15 to 30 international units\/kg IV to increase the circulating antihemophilic factor to 30% to 60% of normal, repeat every 12 to 24 hours for 3 to 4 days or until local hemostasis is achieved; for tooth extraction, a single IV infusion plus adjunctive oral antifibrinolytic therapy within 1 hour of surgery may be adequate<\/li><li><b>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure:<\/b> Xyntha(R): Major surgery, 30 to 50 international units\/kg IV to increase the circulating antihemophilic factor to 60% to 100% of normal, repeat infusions every 8 to 24 hours until wound healing and local hemostasis are achieved<\/li><\/ul>"},{"id":"927833-s-1-6","title":"Dose Adjustments","mono":"<b>increased pulse rate:<\/b> reduce rate of administration or temporarily stop injection "},{"id":"927833-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding, Control and prevention - Hemophilia A<\/li><li>Bleeding, Routine; Prophylaxis - Hemophilia A<\/li><li>Bleeding; Prophylaxis - Hemophilia A - Surgical procedure<\/li><\/ul>"}]},"3":{"id":"927833-s-3","title":"Contraindications\/Warnings","sub":[{"id":"927833-s-3-9","title":"Contraindications","mono":"Life-threatening immediate hypersensitivity, including anaphylaxis, to antihemophilic factor VIII or to any product component, including mouse or hamster protein <br\/>"},{"id":"927833-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- Allergic type hypersensitivity reactions, including anaphylaxis, may occur; discontinue if symptoms develop<\/li><li>-- Factor VIII inhibitors formation (neutralizing antibody); diminished clinical response formation; monitoring recommended<\/li><\/ul>"},{"id":"927833-s-3-11","title":"Pregnancy Category","mono":"Antihemophilic Factor: C (FDA)<br\/>"},{"id":"927833-s-3-12","title":"Breast Feeding","mono":"<ul><li>Antihemophilic Factor: WHO: Compatible with breastfeeding.<\/li><li>Antihemophilic Factor: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"927833-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Musculoskeletal:<\/b>Arthralgia (12% to 25%), Traumatic injury, Limb (10%)<\/li><li><b>Neurologic:<\/b>Headache (21% to 26%)<\/li><li><b>Respiratory:<\/b>Cough (11% to 19%), Nasopharyngitis (17%)<\/li><li><b>Other:<\/b>Fever (21%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis, Factor VIII inhibitor disorder (Xyntha(R), 4.17%; Advate(R), 20%), Hypersensitivity reaction<br\/>"},"6":{"id":"927833-s-6","title":"Drug Name Info","sub":{"0":{"id":"927833-s-6-17","title":"US Trade Names","mono":"<ul><li>Advate<\/li><li>Xyntha<\/li><\/ul>"},"2":{"id":"927833-s-6-19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"927833-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"927833-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"927833-s-7","title":"Mechanism Of Action","mono":"Antihemophilic Factor VIII (Recombinant) [plasma\/albumin-free] (Advate(R)) is a purified glycoprotein consisting of 2332 amino acids  and (Xyntha(R)) consists of 1438 amino acids. Both products are synthesized from Chinese hamster ovary cells. There are no human or animal additives used during the cell culture and purification process. Recombinant Factor VIII temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis  by facilitating the activation of Factor X ultimately causing the formation of thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium.<br\/>"},"8":{"id":"927833-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"927833-s-8-24","title":"Distribution","mono":"<ul><li>Vd, adult: 66.1 to 69 mL\/kg<\/li><li>Vd, pediatric: 66.9 to 67.1 mL\/kg; 0.43 to 0.54 dL\/kg<\/li><\/ul>"},"3":{"id":"927833-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, adult: 3.48 to 4.51 mL\/hr\/kg<\/li><li>Total body clearance, pediatric: 6.29 to 6.62 mL\/hr\/kg; 23% to 42% higher compared with adults<\/li><\/ul>"},"4":{"id":"927833-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adult, 11.2 to 16.7 hours<\/li><li>Pediatric, 6.9 to 11.7 hours; 3% to 27% shorter compared with adults<\/li><\/ul>"}}},"9":{"id":"927833-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>(Xyntha(R)) administer within 3 hours after reconstitution (contains polysorbate 80) or after removal of the grey rubber tip cap from the prefilled dual-chamber syringe<\/li><li>(Xyntha(R)) administer over several minutes; rate of administration is determined by the patient's comfort level<\/li><li>(Advate(R)) do not refrigerate after reconstitution<\/li><li>(Advate(R)) administer with a plastic syringe within 3 hours after reconstitution<\/li><li>(Advate(R)) administer over a period of 5 minutes or less (maximum infusion rate, 10 mL\/minute)<\/li><\/ul>"},"10":{"id":"927833-s-10","title":"Monitoring","mono":"<ul><li>control and prevention of bleeding in patients with hemophilia A is indicative of efficacy<\/li><li>plasma factor VIII levels; for replacement therapy when clinically indicated<\/li><li>pharmacokinetic factor VIII values; to guide dosing and administration (eg, recovery) when clinically indicated.<\/li><li>factor VIII inhibitor levels; if adequate response is not seen with appropriate doses<\/li><\/ul>"},"11":{"id":"927833-s-11","title":"How Supplied","mono":"<ul><li><b>Advate<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Xyntha<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><\/ul>"},"13":{"id":"927833-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to contact a healthcare provider if they feel the medicine is not working.<\/li><li>Encourage patient to consult a healthcare provider prior to travel.<\/li><li>Tell patient to avoid pregnancy and breastfeeding while taking drug and to contact a healthcare provider immediately if pregnancy occurs.<\/li><li>Side effects may include headache, joint pain, fever, cough, diarrhea, vomiting, nausea, and asthenia.<\/li><li>Advise patient to report symptoms of hypersensitivity.<\/li><\/ul>"}}}